Yazarlar : Kim S, Cheong J, Kim D et al

Yayın : Int J Hemato

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/role-induction-and-consolidation-chemotherapy-elderly-acute-myeloid-leukemia-patients?tsid=5

Konu : Lösemi

Literatür İçeriği :  The present study sought to elucidate the role of induction and consolidation therapy in elderly patients. We retrospectively collected data of 477 patients who were aged over 60 years at the time of acute myeloid leukemia (AML) diagnosis. The median overall survival (OS) was 339 days in the induction group (n = 266) and 86 days in the best supportive care group (n = 211) (P < 0.001). In the induction group, the complete remission (CR) rate was 58.3 %, and treatment-related death was 15.4 %. Successful induction was related to good performance [Eastern Cooperative Oncology Group (ECOG<2)] [hazard ratio (HR) 3.215; P = 0.002]. Mortality correlated with failure to achieve CR (HR 4.059; P < 0.001) and poor performance status (ECOG>2) (HR 2.731; P = 0.035). In CR patients, poor karyotype and absence of consolidation (HR 2.313; P = 0.003) correlated with mortality. More than one cycle of consolidation was associated with better OS (P < 0.001). Lack of salvage therapy was associated with mortality in patients who did not achieve CR (HR 3.223; P = 0.005). Intensive induction in patients with good performance and>1 cycle of consolidation after CR may be the best strategy for improving OS in elderly AML patients.

Literatür Arşivi